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Pentoxifylline (PTX) is a methylxanthine that exhib-
its multiple biologic activities, including the inhibi-
tion of collagen synthesis by dermal fibroblasts. Be-
cause some PTX activities have recently been linked 
to transcription factor-mediated regulation of gene 
transcription, we have investigated if PTX acts to 
inhibit collagen synthesis at a transcriptional locus by 
measuring pro collagen mRNA levels and by assaying 
for the presence of an activator of pro collagen gene 
promoters, nuclear factor (NF)-1. The effects of an-
other methylxanthine, pentifylline (PTF) , shown 
herein to be a tenfold more potent inhibitor of col-
lagen synthesis than PTX, and interferon-a, -(3, and 
-11 were studied in parallel. Analysis of extracellular 
protein and RNA from 48-h-treated fibroblasts 
showed that PTX, PTF, and interferons decreased 
al(I), a2(I), and al(III) pro collagens by reducing the 
entoxifylline (PTX) is a substituted methylxanthine 
long used for the treatment of intermittent claudication 
and other conditions involving defective regional mi-
crocirculation. This hemorheologic effect of PTX is 
thought to be mediated by inhibition of cyclic nucle-
otide phosphodiesterases resulting in increased erythrocyte flexibil-
ity and the production by platelets and vascular endothelial cells of 
prostaglandins that enhance local blood flow and promote throm-
bolysis [1]. More recently PTX has been shown to have potential as 
a treatment for several cytokine-mediated diseases, including irri-
tant and contact hypersensitivity, AIDS, transplant-related toxicity, 
and septic shock via inhibition of tumor necrosis factor (TNF)- a 
production or action [2-7]. Regulation of gene transcription ap-
pears to be the primary locus for PTX inhibition of TNF-a 
production and action as PTX decreases levels of mRNA for 
TNF-a in endotoxin-treated monocytes and macrophages, mRNA 
for TNF-a-induced proteins, such as collagenase and 2' -5' oligo-
adenylate synthetase in fibroblasts, and human immunodeficiency 
virus long-terminal repeat-directed gene expression in infected 
cells [6,8,9]. Both the enhancer region of the TNF-a gene and the 
long-terminal repeat region of the human immunodeficiency virus 
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fylline. 
steady-state levels of the corresponding pro collagen 
mRNA transcripts. Reduction of pro collagen mRNA 
levels appeared to be dependent on new protein 
synthesis, as it was prevented by treatment with 
cycloheximide. Assay for the presence of nuclear 
NF-l by gel mobility shift analysis showed that ex-
tracts from interferon, PTX, and PTF-treated fibro-
blasts lacked proteins recognizing the consensus 
DNA binding sequence for NF-1. Taken together, 
these observations suggest interferons and methylx-
anthines may inhibit fibroblast collagen synthesis by 
a common mechanism requiring new protein synthe-
sis that suppresses pro collagen gene transcription 
through down-regulation of NF-1. Key words: cyto-
kines/extracellular matrix/transcription factors. J Invest Der-
matol 104:282-286, 1995 
genome contain binding sequences for the transcnptlOn factor 
NF-KB, whose activation is inhibited by PTX treatment [9,10]. 
We have previously reported that PTX may also have therapeu-
tic potential as an antifibrotic agent, as PTX inhibits the collagen 
and glycosaminoglycan production of normal dermal, sclerodermal, 
and keloidal fibroblasts [11,12]. Our original observations have 
recently been confIrmed by others and extended to fibroblasts 
derived from other cOlmective-tissue disorders involving excess 
extracellular matrix deposition [13,14]. To determine if PTX 
inhibits collagen syntheses by transcription-related mechanisms we 
treated normal dermal fibroblasts with PTX and assayed the levels 
of mRNA transcripts for type I and III procollagen a-chains by 
Northern blotting and assessed the presence of a pro collagen 
gene-activating transcription factor, NF-1, by a gel mobility shift 
assay [15,16]. The effects of PTX treatment were compared to 
those caused by the collagen-synthesis-inhibitory cytokines, inter-
feron (IFN)-a, -{3, -'Y, and a more potent substituted methylxan-
thine collagen-synthesis inhibitor, pentifylline (PTF) [17,18]. Our 
results indicate that PTX, PTF, and IFN s all decrease pro collagen 
synthesis, pro collagen mRNA levels, and the presence of NF-l. 
MATERIALS AND METHODS 
Reagents PTX and PTF were obtained from Sigma Chemical Co. , St. 
Louis, MO. Recombinant human IFN-0'2b' -{3, and -T' derived from 
Escherichia coli were obtained from Schering, Kenilworth, NJ, Janssen 
Biochirnica, Flanders, NJ; and Genentech, South San Francisco, CA, 
respectively. Plasmids Hf667, Hf32, and Hf934 containing eDNA inserts 
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complementary to mRNAs for human pro collagen a1 (I), a2(I), and a1 (III), 
respectively, were from the American Type Culture Collection, Rockville, 
MD, and a 1.0-kb cDNA probe for human glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was supplied by Clontech Inc., Palo Alto, CA. 
Goat anti-type I collagen IgG was from Fisher BioTech, Pittsburgh, PA, and 
murine monoclonal IgG1 to human type III collagen from Chemicon 
International, Temecula, CA. PTX, PTF, and IFN s diluted to desired 
concentrations with Dulbecco's modified Eagle's medium (DMEM) con-
taining 0.1 % human serum albumin were added directly to fibroblast 
cultures. 
Fibroblast Cultures Primary fibroblast cultures were initiated by the 
explant technique from full-thickness adult facial and mammary skin 
removed during cosmetic surgery and maintained in DMEM containing 25 
mM HEPES, 2 mM glutamine, 100 Vlml penicillin, 100 J.Lg/ml streptomy-
cin, and 10% heat-inactivated fetal bovine serum (FBS) (Whittaker Bio-
products, Walkersville, MD) at 37°C in a 5% CO2 humidified atmosphere. 
Fibroblasts were subcultured by trypsinization and studies were performed 
on cells between the third and ninth passages. 
Assay of Fibroblast Collagen Production Collagen produced during 
the terminal 24 h of a 48-h treatment period by steady-state, confluent 
fibroblast microcultures in DMEM plus ascorbic acid and no FBS was 
assessed by 3H-proline incorporation into pepsin-resistant, salt-precipitated 
extracellular and cell-associated collagen as we and others have previously 
described [8,11,12,18]. Each experimental condition was done in triplicate 
wells and averaged results are expressed as disintegrations per minute (dpm) 
of 3H-collagen per 103 cells ~ SD. Harvested fibroblasts were always 
greater than 95% viable by trypan blue exclusion. 
Gel Electrophoresis and Western Blotting Aliquots of protease-
inhibitor treated supernatant media from unradiolabeled microcultures were 
electrophoresed on 12% sodium dodecylsulfate-polyacrylamide gels after 
reduction with 2-mercaptoethanol using modified Laemmli conditions [19]. 
Supernatants were concentrated 20 times for analysis of collagens and 
aliquot volumes were standardized for cell number. Following semi-dry 
transfer to neutral nylor. membrane, Western immunoblots were prepared 
by incubation with primary antibodies to collagen type I or III and 
secondary alkaline phosphatase-conjugated antibodies, followed by detec-
tion with a chemiluminescent dioxetane substrate system (Rad-Free, Schlei-
cher & Schuell, Keene, NH). Blot signals detected on x-ray film were 
quantified by densitometry. 
RNA Isolation and Northern Blotting Total cellular RNA was ex-
tracted from fibroblast monolayers grown in 25-cm2 flasks by a single-step 
method of RNA isolation [20] with a commercially available acid guani-
dinium thiocyanate-phenol extraction reagent (Tri Reagent, Molecular 
Research Center, Cincinnati, OH). Five-microgram aliquots of RNA were 
glyoxylated and fractionated on a 1.0% agarose gel in 10 mM phosphate 
buffer, pH 7, followed by vacuum blotting onto a nylon membrane (Nytran, 
Schleicher & Schuell) using methods similar to those previously described 
[21]. Membranes were hybridized overnight at 42°C against cDNA probes 
labeled by random priming with digoxigenin-modified dVTP [22] in a 
hybridization solution containing 50% formamide, 5 X SSPE, 1 X Den-
hardt's solution, 100 J.Lg/ml denatured salmon sperm DNA, and 0.1 % 
sodium dodecylsulfate. Following low- and high-stringency washes signals 
were generated by incubation with an anti-digoxigenin antibody coupled to 
alkaline phosphatase and a chemiluminescent dioxetane substrate (Genius 
System, Boehringer-Mannheim, Indianapolis, IN) [22]. Hybridization sig-
nals detected on x-ray film were quantitated by densitometry and are 
reported relative to the expression of the "housekeeping gene," GAPDH 
[23]. The proal(I) collagen probe was random primed from the 1.8-kb 
EcoRI/EcoRI fragment of plasmid Hf677 [24], the proa2(I) collagen probe 
from the 2.2-kb AatII/EcoRI fragment of plasmid Hf32 [25], and the 
proal(III) collagen probe from the 0.7- and 0.6-kb EcoRI/HindIII frag-
ments of plasmid Hf934 [26]. 
Gel Mobility Shift Assay The binding of nuclear proteins extracted 
from 25-cm2 cultures of confluent fibroblasts to a digoxigenin-labeled 
22-mer double-stranded oligonucleotide containing the consensus binding 
sequence for NF-l (5'-TGGCANsGCCAA-3') (Promega, Madison, WI) 
was determined by resolution of oligonucleotide-protein complexes from 
free oligonucleotide by native polyacrylamide gel electrophoresis as we 
have previously described in detail, with the following modifications [27]: 
the binding assay mixture contained 3 J.Lg of nuclear protein extract and poly 
dG:dC in place of poly dI:dC in a total volume ofl0 J.LI; and electrophoresis 
and pre-electrophoresis were performed at 200 V with recirculation of the 
buffer. 
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RESULTS 
PTX and Other Xanthine Analogues Decrease Fibroblast 
Collagen Production Although our previous in vitro studies 
indicate PTX may be a potential antifibrotic agent, the high 
concentrations of PTX necessary to suppress fibroblast collagen 
synthesis suggest that routine oral doses of PTX would be ineffec-
tive as an antifibrotic therapy [11 ,12]. To address this problem, we 
compared the collagen synthesis-inhibitory potency of PTX and 
several other subtituted methylxanthines using the fibroblast mi-
crowell collagen assay in an attempt to fmd a more potent 
collagen-synthesis inhibitory xanthine. As shown in Fig 1, caffeine 
(1 ,3 ,7-trimethylxanthine) , theophylline (1 ,3-dimethylxanthine) , 
theobromine (3,7 -dimethylxanthine) and 3-isobutyl-l-methylxan-
thine all inhibited fibroblast collagen synthesis with a 50% inhibi-
tory dose (IDso) of approximately 100 p,g/ml, similar to that of 
PTX (1-[5-oxohexyl]-3,7-dimethylxanthine). The parent com-
pound, xanthine, was insoluble at 1000 p,g/ml but showed no 
inhibition of collagen synthesis at 100 p,g/ml, whereas hypoxan-
thine had an IDso greater than 1000 p,g/ml. In contrast, the PTX 
precursor compound, PTF (1-hexyl-3, 7 -dimethylxanthine), was 
found to be ten times more potent than PTX inhibiting fibroblast 
collagen synthesis with an IDso of approximately 10 p,g/ml. 
Western Blot Analyzed Extracellular Collagen Production 
Is Decreased by IFNs9 PTX9 and PTF To confirm the validity 
of our results obtained by the 3H-proline incorporation assay, and 
to determine the collagen types inhibited by PTX and PTF we 
analyzed fibroblast supernatant media for types I and III collagens 
by immunoblot analysis. The effects of IFN-a, -{3 and -yon types 
I and III collagen synthesis was also assessed for comparison. We 
found that the only proteins recognized by antibodies to types I and 
III collagens migrated with molecular weights of approximately 
160-170 kD, indicating that fibroblast supernatant media contained 
predominantly full-length procollagens. The polyclonal antibody to 
type I collagen reacted preferentially with the lower-molecular-
weight a2 chain of procollagen I. As shown, in Fig 2, treatment 
with 100 ng/ml ofIFNs, 1000 p,g/ml PTX, or 100 p,g/ml PTF for 
48 h decreased the amount of both types I and III procollagens 
present in supernatant media from normal dermal fibroblasts. All 
agents decreased both the al and a2 chains of type I procollagen. 
The percentage decrease induced by IFN-a, -{3, -y, PTX, and PTF 
as assessed by densitometry are for procollagen I, 34, 49, 59, 84, 
and 76, respectively; and for procollagen 111,51,16,65,97, and 97, 
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Figure 1. PTX and other xanthine analogues decrease normal 
dermal fibroblast collagen production. Collagen production was as-
sessed by measuring 3H-proline incorporation into cellular and extracellular 
pepsin-resistant, salt-precipitated collagen during the terminal 24 h of a 48-h 
treatment with xanthines as described in Materials and Methods. PTF (t-. ), 
PTX (.), caffeine (0), theophylline (_), theobromine (0), isobutylmeth-
ylxanthine (e) , hypoxanthine ( 0 ), xanthine ( . ). Points are the mean of 
triplicate determinations and SD were less than 15%. Data was confirmed in 
two additional experiments. 
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Figure 2. IFNs, PTX, and PTF decrease extracellular type I and III 
procollagen. Supernatant media from fibroblast microcultures were har-
vested after 48 h treatment and analyzed by Western immunoblot analysis. 
Untreated fibroblasts (1), fibroblasts treated with 100 nglml ofIFN-a (2), 
100 ng/ml IFN-t3 (3), 100 nglml IFN-'}' (4), 1000 J-Lg/ml PTX (5), or 100 
J-Lg/ml PTF (6). 
collagens in a ratio of 5:1, then the observed decreases are 
approximately proportional to the decrease in total collagen syn-
thesis determined by the 3H-proline incorporation assay shown in 
Fig 1, and reported previously [11-13,17,18]. Moreover, PTX and 
PTF at the tested concentrations appear to be more effective 
inhibitors of collagen synthesis than IFNs at 100 ng/ml. 
IFNs, PTX, and PTF Decrease Fibroblast Pro collagen 
mRNA Levels To determine if IFN, PTX, and PTF-inhibited 
procollagen synthesis is due to decreased steady-state pro collagen 
mRNA levels, Northern blot analysis was performed using RNA 
extracted from dermal fibroblasts that were either untreated or 
treated with IFNs, PTX, or PTF for 48 h. Blots were incubated 
with cDNA probes that hybridized to mRNA transcripts of 5.8 and 
4.8 kb for proal (I) collagen, 5.1 and 4.6 kb for proa2(1) collagen, 
5.4 and 4.8 kb for proal(llI) collagen, and 1.4 kb for the 
"housekeeping protein" GAPDH [23-26]. The resultant Northern 
blots shown in Fig 3 demonstrate that the steady-state levels of all 
three assayed procollagen mRNA transcripts were decreased by 
treatment with IFN s, PTX, or PTF. Only minimal effects on 
GAPDH transcripts were noted, with IFN s causing small decreases 
and PTX and PTF small increases in transcript levels. When the 
levels of pro collagen mRNA transcripts are corrected for these 
slight changes in GAPDH transcript expression, the percentage 
decrease in procollagen mRNA levels induced by IFNa, -f3, -y, 
PTX, and PTF as assessed by densitometry are, for pro collagen 
0'1(1), 60, 60, 80, 95, and 95, respectively; procollagen 0'2(1), 14, 
33,52,64, and 80, respectively; and pro collagen 0'1(111), 31, 33, 71, 
92, and 98, respectively. When IFN-a, -f3, -y, PTX, and PTF were 
tested in the presence of 2 J.Lg/ml of protein synthesis inhibitor 
cycloheximide, no decrease in procollagen 0'1 (I) mRNA transcripts 
was observed (Fig 4). 
123456 
Procollagen al (I) 
Procollagen a2(1) 
Procollagen al (III) 
GAPDH 
Figure 3. IFNs, PTX, and PTF decrease levels of type I and III 
procollagen a-chain mRNA transcripts. Fibroblasts treatment as de-
scribed in Fig 2. Procollagen transcripts were detected with cDNA probes 
prepared from plasmids Hf677 [al(I)], Hf32 [a2(I)], and Hf943 [al(III)]. 
Detections were performed simultaneously with a cDNA probe for GAPDH 
mRNA transcripts as described under Northern Blotting. 
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Figure 4. IFNs, PTX, and PTF do not decrease levels of pro colla-
gen al(l) mRNA in fibroblasts additionally treated with 2 ILg/ml of 
cycloheximide. Treatments as described in Fig 2 . 
I 
IFNs, PTX, and PTF Decrease Fibroblast Expression of 
NF-1 NF-l is a nuclear protein that has been implicated as a 
transcription factor required for basal and transforming growth 
factor (TGF-f3)-stimulated procollagen gene promoter activation ! 
[15,16,28,29]. To determine if IFN, PTX, and PTF inhibition of 
pro collagen mRNA levels can be correlated with reduced NF-l 
expression, we analyzed nuclear protein extracts from untreated 
fibroblasts and fibroblasts treated for 48 h with IFNs, PTX, or PTF 
for the presence of factors binding an oligonucleotide containing 
the consensus binding sequence for NF-l using the gel mobility 
shift assay [27]. As shown in Fig 5 , nuclear extracts from untreated 
fibroblasts (lane 2) contain proteins that bind a portion of the 
labeled NF-l consensus oligonucleotide, resulting in the detection 
of a DNA-protein complex of shifted mobility that is composed of 
labeled oligonucleotide bound to protein NF-l. In contrast to 
untreated fibroblasts, nuclear extracts from IFN-a, -f3, -y, PTX, or 
PTF-treated fibroblasts (lanes 3-7) produced no complexes of 
shifted mobility indicating the absence of proteins in the extracts of 
treated fibroblasts that interact with NF-l binding sites. As shown 
in Fig 6, the shifted DNA-protein complexes appear to be specific 
for NF-l protein as simultaneous incubation with a lO X concen-
tration of unlabeled NF-l oligonucleotide prevents detection of 
shifted labeled oligonucleotide-protein complexes using nuclear 
extracts from untreated, IFN-a-treated, and PTX-treated fibro-
blasts. Furthermore, the shifted DNA-protein complex appears to 
be specific for NF-l protein, as we have previously demonstrated 
that simultaneous incubation with a lOX concentration of unla-
beled NF-l oligonucleotide prevents detection of shifted oligonu-
cleotide-protein complex [27], whereas unrelated oligonucleotides 
SP-l and AP-2 do not prevent detection (data not shown). Direct 





Figure 5. IFN, PTX, and PTF-treated fibroblasts lack proteins 
binding a NF-l consensas oligonucleotide. Nuclear extracts from 
untreated fibroblasts (2) or fibroblasts treated for 48 h with IFN-a (3), -13 
(4), -'}' (5), PTX (6), or PTF (7) at the concentrations listed in Fig 2. 
Fibroblast nuclear protein extracts were incubated with labeled NF-l 
consensus oligonucleotide, followed by electrophoresis, blotting, and de-
tection as described in Materials and Methods. Lane 1 is labeled NF-l 
consensus oligonucleotide without nuclear extract. 
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Figure 6. Excess u nlabeled NF-l oligonucleotide specifically 
blocks IFN- an d P TX-treated fibroblast pro teins from binding to 
labeled NF-l co nsensus oligonucleotide. Nuclear extracts from un-
treated fibroblasts (1 and 4) or fibroblasts treated for 48 h with IFN-a (2 and 
5) or PTX (3 and 6) at the concentrations listed in Fig 2 . Fibroblast nuclear 
protein extracts were incubated with labeled NF-1 consensus oligonucleo-
tide in the presence (1, 2, and 3) and absence (4, 5, and 6) of a tenfold 
concentration of unlabeled oligonucletide , followed by electrophoresis, 
blotting, and detection as described in Materials and Methods. 
labeled oligonucleotide and nuclear extracts from untreated fibro-
blasts did not prevent oligonucleotide-protein complex formation, 
indicating these agents do not physically block NF-1-DNA inter-
action (data not shown). 
DISCUSSION 
IFNs-a, -{3, -)I and PTX are agents that we and others have 
previously reported to decrease the collagen synthesis of fibroblasts 
derived from both normal and fibrotic skin [11-13,17,18]. In this 
report we have demonstrated that other methylxanthines also 
inhibit fibroblast collagen production and that one compound, 
PTF, is a tenfold more potent inhibitor than PTX. Although several 
reports indicate that IFN-)I inhibits fibroblast collagen production 
by decreasing both basal and TGF-{3-stimulated levels of procolla-
gen mRNAs through both transcriptional and post-transcriptional 
process, the mechanisms by which IFN-a, -{3, and PTX inhibit 
collagen synthesis have not been widely studied [29-32]. Herein, 
we have investigated how IFN-a, -{3 , and PTX inhibit fibroblast 
collagen synthesis, and report that IFN-a, -(3 and -)I, as well as PTX 
and PTF, all decrease the synthesis of type I and III procollagens by 
depressing procollagen 0'1 (I), 0'2(1), and 0'1 (III) mRNA levels in 
treated fibroblasts. These inhibitory effects on mRNA levels were 
observed for both basal (Fig 3) and TGF-{3-stimulated fibroblasts 
(data not shown). Reduction of procollagen mRNA transcript 
levels appeared to be dependent on new protein synthesis as 
simultaneous treatment of fibroblasts with cycloheximide blocks 
the suppressive effect of IFN-a, -{3, -)I, PTX, and PTF on procol-
lagen 0'1 (I) mRNA levels (Fig 4). The nature of these newly 
synthesized proteins and how they function to decrease pro collagen 
mRNA levels is unknown, but they could act transcriptional either 
as direct procollagen gene repressors or indirectly as repressors of 
genes coding for transcription factors that activate pro collagen 
promoters. Alternatively, newly synthesized proteins could de-
crease procollagen mRNA levels by decreasing mRNA stability or 
by enhancing mRNA decay. 
One protein thought to regulate levels of pro collagen mRNAs is 
NF-1, a transcription factor reportedly required for basal and 
TGF-{3-stimulated activation of procollagen promoters for murine 
0'1(1),0'2(1), and 0'1(111) and human 0'2(1) genes [15,16,28,29,31]. 
Therefore, we analyzed fibroblast nuclear protein extracts for NF-1 
using the gel mobility shift assay. Our results showed that, although 
nuclear extracts from untreated fibroblasts contain proteins binding 
an oligonucleotide containing the consensus sequence for NF-1 
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binding, extracts from fibroblasts treated with IFN-a, -{3, - )I, PTX, 
and PTF lacked oligonucleotide-binding proteins (Fig 5), suggest-
ing these agents inhibit fibroblast collagen synthesis by reducing the 
presence of nuclear NF-1. Whether nuclear extracts contain no 
NF-1 due to enhanced degradation, inhibited . synthesis, or transfer 
to the cytoplasm or whether NF-l is present but in an inactive form 
that does not bind the oligonucleotide cannot be determined from 
our gel mobility shift analysis. Modulation of NF-1 synthesis or 
degradation may be the more likely hypothesis, as to date NF-1 has 
not been reported to exist in an inactive form nor to undergo 
nucleus-cytoplasm translocation [33]. However, both PTX and 
IFNs have been shown to mediate the expression of other genes 
through the regulation of transcription factor activation [9,10,34]. 
Overall our results suggest that IFNs and methylxanthines may 
act through a common mechanism to inhibit fibroblast collagen 
synthesis, i.e., inhibition of procollagen mRNA levels by suppres-
sion of procollagen gene transcription through down-regulation of 
transcription factor NF-1. This theory is supported by experiments 
showing that when IFNs and PTX are tested in combination, the 
inhibitory effects on collagen synthesis are only additive and not 
potentiating (data not shown). Moreover, our results showed that 
PTF, PTX, and other tested methylxanthines inhibit fibroblast 
collagen synthesis in relative potency to their activities as nonspe-
cific cyclic nucleotide phosphodiesterase inhibitors [35]. Inhibition 
of phosphodiesterases can affect gene transcription, as increased 
cyclic adenosine monophosphate and cyclic GMP levels activate 
protein kinase A and G, which activate latent proteins, including 
transcription factors, by serinelthreonine phosporylation [36]. 
Likewise, early reports also indicate that IFN-a/ {3 can also increase 
the levels of cyclic AMP and cyclic GMP in cultured cells, and more 
recently IFN-a, -(3 and -)I have been reported to activate gene 
promoter regulatory proteins through tyrosine kinase-mediated 
phosphorylation [34,37]. Thus, the common mechanism by which 
IFNs and PTX/PTF inhibit fibroblast collagen synthesis likely 
involves the interaction of mixed kinase signaling pathways result-
ing in phosphorylation of a common protein mediator, which 
ultimately leads to down-regulation of NF-1. 
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